The efficacy of mepolizumab treatment on rhinovirus induced asthma exacerbations - Mepolizumab and virus-induced asthma exacerbations

Academisch Medisch Centrum0 个研究点目标入组 48 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Age between 18 * 50 years
•Intermittent or mild persistent asthma according to the criteria by the Global Initiative for Asthma
•Non-smoking or stopped smoking more than 12 months ago and * 5 pack years
•Clinically stable, no history of exacerbations within the last 6 weeks prior to the study
•Steroid-naïve or those patients who are currently not on corticosteroids and have not taken any corticosteroids by any dosing-routes within 2 weeks prior to the study
•Baseline FEV1 at least 80% of predicted
•PC20histamine < 9.8 mg/ml
•Positive skin prick test to one or more of the 12 common aeroallergen extracts

•Moderate to severe asthma patients (according to the GINA guidelines)
•Patients who have had an exacerbation during the past 6 months, as indicated by a course of systemic steroids or antibiotics
•Presence of antibodies directed against rhinovirus type 16 (titer > 4)
•Smokers or ex-smokers (< 12 months or > 6 pack years)
•Women who are pregnant, lactating or who have a positive urine pregnancy test at visit 1
•Patients who are in close contact with young children (< 2 years), either professional or family related
•Participation in any clinical investigational drug treatment protocol within the preceding 3 months

发起方